Safety and tolerability of pneumococcal vaccines in children

References

• Esposito S, Principi N, ESCMID Vaccine Study Group (EVASG). Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiol. 2015;10:1599–1607.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal disease; 2015 [cited 2015 Dec 16]. Available from: http://www.who.int/ith/diseases/pneumococcal/en/.
   Google Scholar
• Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans. Clin Microbiol Infect. 2012;18(Suppl 5):15–24.
   PubMed Web of Science ®Google Scholar
• Borrow R, Heath PT, Siegrist C-A. Use of pneumococcal polysaccharide vaccine in children: what is the evidence? Curr Opin Infect Dis. 2012;25:292–303.
   PubMed Web of Science ®Google Scholar
• Fattom A. Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man. Adv Exp Med Biol. 1995;383:131–139.
   PubMedGoogle Scholar
• Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res. 2015;2015:591580.
   PubMed Web of Science ®Google Scholar
• Dagan R. Serotype replacement in perspective. Vaccine. 2009;27(Suppl 3):C22–C24.
   Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med. 2014;2:717–727.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Pelton SI. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr. 2011;23:98–104.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535–543.
   PubMed Web of Science ®Google Scholar
• Sobanjo-ter Meulen A, Vesikari T, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:186–194.
   PubMed Web of Science ®Google Scholar
• Lopalco PL, DeStefano F. The complementary roles of phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33:1541–1548.
   PubMed Web of Science ®Google Scholar
• Center KJ, Strauss A. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction. Vaccine. 2009;27:3281–3284.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine. 2011;29:2287–2295.
   PubMed Web of Science ®Google Scholar
• Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis. 2011;52:736–742.
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. Jama. 1998;280:1685–1689.
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Balloch A, et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 2010;28:3341–3349.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Levine OS, Elliott JA, et al. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis. 1999;5:828–831.
   PubMed Web of Science ®Google Scholar
• Riley ID, Lehmann D, Alpers MP, et al. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet. 1986;2:877–881.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal vaccination: who needs it? 2015 [cited 2015 Dec 18]. Available from: http://www.cdc.gov/vaccines/vpd-vac/pneumo/vacc-in-short.htm.
   Google Scholar
• Sigurdardottir ST, Ingolfsdottir G, Davidsdottir K, et al. Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine. Pediatr Infect Dis J. 2002;21:548–554.
   PubMed Web of Science ®Google Scholar
• Anderson EL, Kennedy DJ, Geldmacher KM, et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr. 1996;128:649–653.
   PubMed Web of Science ®Google Scholar
• Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine. 2000;18:2359–2367.
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2006;25:920–929.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal conjugate vaccine study group. Pediatrics. 2000;106:965–972.
   PubMed Web of Science ®Google Scholar
• Nurkka A, Joensuu J, Henckaerts I, et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:1008–1014.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser permanent vaccine study center group. Pediatr Infect Dis J. 2000;19:187–195.
   PubMed Web of Science ®Google Scholar
• DeStefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull WHO. 2008;86:373–380.
   PubMed Web of Science ®Google Scholar
• Black S, France E, Lewis E, et al. Postmarketing assessment of Prevnar, 7-valent pneumococcal conjugate vaccine (PNCV7). Presented at 2006 Annual Meeting of the Pediatric Academic Societies; 2006 Apr 29; 2006 May 2; San Francisco, CA.
   Google Scholar
• Black S, France EK, Center KJ, et al. Kawasaki disease (KD) following immunization: case series from a large safety surveillance study of Prevnar, 7-valent pneumococcal conjugate vaccine. Presented at the 44th Annual Meeting of the Infectious Disease Society of America; 2006 Oct 12–15; Toronto, Canada.
   Google Scholar
• Center KJ, Hansen JR, Lewis E, et al. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009;28:438–440.
   PubMed Web of Science ®Google Scholar
• Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. Jama. 2004;292:1702–1710.
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR–11):1–18.
   PubMedGoogle Scholar
• Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013;31:5289–5295.
   PubMed Web of Science ®Google Scholar
• A phase I/II, 2-stage, randomized, double-blind trial of the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (serotypes1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in healthy infants; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00205803.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in the United States; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00373958.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial of the safety, tolerability, and immunologic non-inferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in Germany; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00366340.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal Conjugate vaccine in healthy infants given with routine pediatric vaccinations in France; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00366678.
   Google Scholar
• A phase 3, randomized, double-blind trial evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 in healthy infants given in a 2-,3-, 4-, and 12-month schedule with routine pediatric vaccinations; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00366548.
   Google Scholar
• A phase 3, randomised, active-controlled, double-blind trial evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine paediatric vaccinations in India; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00452790.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in Spain; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00368966.
   Google Scholar
• A phase 3, randomised, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00464945.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of three lots of 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in the United States; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00444457.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with a meningococcal C-tetanus toxoid conjugate vaccine and other routine pediatric vaccinations in Spain; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00474539.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in Canada; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00475033.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in the United Kingdom; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00384059.
   Google Scholar
• A phase 3, randomized, active-controlled, double-blind trial evaluating the safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants given with routine paediatric vaccinations in Italy; 2013 [cited 2015 Dec 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00366899.
   Google Scholar
• Hauck FR, Tanabe KO. International trends in sudden infant death syndrome: stabilization of rates requires further action. Pediatrics. 2008;122:660–666.
   PubMed Web of Science ®Google Scholar
• Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis. Vaccine. 2013;31:5349–5358.
   PubMed Web of Science ®Google Scholar
• Amdekar YK, Lalwani SK, Bavdekar A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India. Pediatr Infect Dis J. 2013;32:509–516.
   PubMed Web of Science ®Google Scholar
• Weckx LY, Thompson A, Berezin EN, et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012;30:7566–7572.
   PubMed Web of Science ®Google Scholar
• Huang LM, Lin TY, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine. 2012;30:2054–2059.
   PubMed Web of Science ®Google Scholar
• Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine(PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine. 2011;29:9675–9683.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Block SL, Baker SA, et al. PCV13 infant study group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;25:866–875.
   Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–4203.
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493–e505.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017–1026.
   PubMed Web of Science ®Google Scholar
• Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80–e90.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Czajka H, Center KJ, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015;135:e876–e886.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013;31:2578–2583.
   PubMed Web of Science ®Google Scholar
• Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011. Vaccine. 2012;30:2024–2031.
   PubMed Web of Science ®Google Scholar
• Plosker GL. 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine: a review in infants and children. Paediatr Drugs. 2014;16:425–444.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:66–76.
   PubMed Web of Science ®Google Scholar
• Prymula R, Siegrist CA, Chlibek R, et al. Paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374:1339–1350.
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28:89–96.
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Alberto E, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J. 2011;30:69–72.
   PubMed Web of Science ®Google Scholar
• Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28:S109–S118.
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Hogh B, Bergsaker MR, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valentpneumococcal nontypeable Haemophilus influenza protein D conjugate vaccine. Pediatr Infect Dis J. 2009;28:276–282.
   PubMedGoogle Scholar
• Vesikari T, Karvonen A, Lindblad N, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine co-administered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J. 2010;29:47–56.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitides serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28:77–88.
   PubMed Web of Science ®Google Scholar
• Lagos RE, Muñoz AE, Levine MM, et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccine. 2011;7:511–522.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Synflorix: summary of product characteristics; [updated 2014 Apr 25; cited 2015 Dec 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/000973/WC500054346.pdf.
   Google Scholar
• Dagan R, Melamed R, Zamir O, et al. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J. 1997;16:1053–1059.
   PubMed Web of Science ®Google Scholar
• King JC Jr, Vink PE, Farley JJ, et al. Safety and 32. immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics. 1997;99:575–580.
   PubMed Web of Science ®Google Scholar
• Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180:1171–1176.
   PubMed Web of Science ®Google Scholar
• Dagan R, Kayhty H, Wuorimaa T, et al. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J. 2004;23:91–98.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–1348.
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139–1146.
   PubMed Web of Science ®Google Scholar
• Wuorimaa T, Dagan R, Eskola J, et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr Infect Dis J. 2001;20:272–277.
   PubMed Web of Science ®Google Scholar
• Kanra G, Viviani S, Yurdakök K, et al. Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine. Pediatr Int. 2003;45:314–318.
   PubMed Web of Science ®Google Scholar
• Miyaji EN, Oliveira ML, Carvalho E, et al. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70:3303–3326.
   PubMed Web of Science ®Google Scholar